Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (NCT07298421) titled 'A Study to Assess the Pharmacokinetics, Effectiveness and Safety of Afimkibart for Induction and Maintenance Therapy in Children With Moderately to Severely Active Crohn's Disease' on Dec. 19, 2025.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).
Primary Sponsor: Hoffmann-La Roche
Condition:
Moderately to Severely Active Crohns Disease
Intervention:
Drug: Afimkibart
Recruitment Status: Not recruiting
Phase: Phase 3
Date of First Enrollment: ...